The global insulin delivery devices market size was estimated at USD 16.42 billion in 2023 and is projected to reach USD 28.06 billion by 2030, growing at a CAGR of 7.89% from 2024 to 2030. This robust market growth is primarily driven by the rising global prevalence of diabetes, which has significantly increased the demand for advanced, reliable, and user-friendly solutions for effective diabetes management. As the number of patients requiring long-term insulin therapy continues to rise, healthcare providers and patients alike are seeking innovative delivery devices that improve convenience, accuracy, and treatment adherence.

Technological advancements play a critical role in supporting market expansion, particularly through the development of insulin delivery devices that are more efficient, minimally invasive, and customized to address individual patient needs. Manufacturers are increasingly focused on enhancing device comfort, precision, and ease of use, thereby reducing the burden associated with daily insulin administration. These advancements help improve patient compliance and overall treatment outcomes.

In addition, the integration of digital technology with insulin delivery devices is expected to further accelerate market growth. This trend includes the increasing adoption of Continuous Glucose Monitoring (CGM) systems that function in coordination with insulin delivery devices. Such integrated systems enable real-time glucose monitoring and automated insulin adjustments, allowing for more responsive and personalized diabetes management. The ability to continuously track glucose levels and dynamically adjust insulin dosing enhances safety and helps maintain optimal glycemic control.

Technological progress in diabetes care has substantially transformed insulin delivery methods, shifting from conventional injection-based approaches to advanced, minimally invasive solutions. In earlier stages, insulin administration posed challenges in maintaining stable blood glucose levels due to limited monitoring and dosing precision. The introduction of insulin pens marked a significant improvement by simplifying self-administration and minimizing patient discomfort. Subsequently, the development of insulin pumps enabled continuous insulin infusion, offering better glucose regulation and improved flexibility in daily management.

A major breakthrough in this evolution was the introduction of Continuous Glucose Monitoring (CGM) devices, which provide real-time glucose data and valuable insights into glucose trends. This innovation laid the foundation for Artificial Pancreas Systems (APS), which integrate CGM data with insulin pumps to enable automated insulin delivery, closely replicating the natural function of the pancreas. Bionic technology, which combines biological processes with advanced artificial systems, has been instrumental in advancing insulin delivery solutions. It supports the functionality of APS by leveraging sensors, algorithms, and automated pumps to deliver precise insulin doses with minimal manual input.

Key Market Trends & Insights:

• The North America insulin delivery devices market held the largest share of 40.73% in 2023, reflecting the region’s strong adoption of advanced diabetes management technologies. This dominant position can be attributed to factors such as a high prevalence of diabetes, well-established healthcare infrastructure, widespread access to innovative medical devices, and favorable reimbursement policies that support the use of insulin delivery systems across clinical and home-care settings.

• Within North America, the insulin delivery devices market in the U.S. held the largest market share in 2023. The country’s leadership is supported by early adoption of technologically advanced devices, strong presence of key market players, increased patient awareness regarding diabetes management, and continuous investments in research and development aimed at improving insulin delivery solutions.

• By product, insulin pens captured the largest market share of 43.68% in 2023. Their widespread use is driven by advantages such as ease of administration, portability, accurate dosing, and improved patient convenience compared to traditional syringes. Insulin pens are increasingly preferred by both patients and healthcare professionals, particularly for self-administration, which has contributed significantly to their strong market position.

• By end use, the hospitals and clinics segment is expected to witness the fastest CAGR of 8.42% during the forecast period. This anticipated growth is driven by the rising number of diabetes-related hospital visits, increasing diagnosis rates, and the growing reliance on professional healthcare settings for insulin initiation and management. Additionally, hospitals and clinics play a crucial role in patient education, device training, and the adoption of advanced insulin delivery technologies, further supporting segment growth over the forecast period.

Order a free sample PDF of the Insulin Delivery Devices Market Intelligence Study, published by Grand View Research.

Market Size & Forecast:

• 2023 Market Size: USD 16.42 Billion

• 2030 Projected Market Size: USD 28.06 Billion

• CAGR (2024-2030): 7.89%

• North America: Largest market in 2023

Key Companies & Market Share Insights:

The insulin delivery devices market represents a dynamic and rapidly evolving segment of the medical device industry, largely driven by the rising global prevalence of diabetes. This market encompasses a wide range of devices developed to administer insulin efficiently to individuals with diabetes, with the primary objective of maintaining optimal blood glucose levels. As the burden of diabetes continues to grow worldwide, the need for reliable and effective insulin delivery solutions has become increasingly critical.

With diabetes management steadily transitioning toward more patient-centric approaches, there is a growing preference for insulin delivery methods that are convenient, efficient, and minimally invasive. This shift has significantly boosted the demand for advanced and innovative insulin delivery devices that enhance treatment adherence and improve patient comfort. Technological progress has further supported this trend by enabling the development of devices that offer greater precision, ease of use, and improved integration with digital health solutions.

The insulin delivery devices market is highly competitive, characterized by continuous innovation and frequent product enhancements. Companies operating in this space are actively expanding and diversifying their product portfolios to address the varying needs of diabetes patients across different age groups and care settings. Market share is largely influenced by factors such as the level of product innovation, user-friendliness, availability across healthcare systems, and the extent of insurance coverage and reimbursement support.

Leading players such as Novo Nordisk, Sanofi, and Eli Lilly hold a dominant position in the market, supported by their broad product offerings, strong global distribution networks, and well-established brand reputation. Their long-standing presence and consistent investment in research and development have enabled them to maintain a competitive edge. At the same time, smaller companies and emerging startups are gaining traction by targeting niche segments within the market. These players are focusing on innovative solutions such as wearable insulin delivery devices and smart insulin pens, which offer enhanced connectivity and personalization. By addressing unmet patient needs and leveraging advanced technologies, these newer entrants are increasingly challenging the dominance of established market leaders.

Key Players

• Novo Nordisk A/S

• Sanofi

• Eli Lilly and Company

• Ypsomed AG

• Medtronic

• Insulet Corporation

• B. Braun SE

• Owen Mumford Ltd.

• Tandem Diabetes Care, Inc.

• BD (Becton, Dickinson, and Company)

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

In conclusion, the insulin delivery devices market is experiencing strong growth due to the increasing global prevalence of diabetes and the rising demand for advanced, easy-to-use treatment options. Ongoing technological advancements—especially in digital integration and less invasive delivery methods—are enhancing the functionality and appeal of these devices. The market remains competitive, with larger established players maintaining a significant presence while smaller innovators continue to introduce niche solutions. Overall, the industry outlook is positive, driven by continuous innovation, expanding product applications, and greater adoption in both clinical and homecare settings.